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OBJECTIVE: To reduce the use of amoxicillin-clavulanate
after high-resistance rates in Escherichia coli were detected.
DESIGN: Intervention study; the interventions were intro-
duced successively over a 4-year period while closely monitoring
the resistance patterns.
SETTING: A 260-bed acute-care hospital in Switzerland.
INTERVENTIONS: Introduction of therapeutic guidelines
for specific departments or indications, which proposed alternative
antibiotics to amoxicillin-clavulanate. The perioperative prophylac-
tic use of amoxicillin-clavulanate was eliminated completely.
RESULTS: The absolute amount of amoxicillin-clavulanate
consumed decreased by 23%, from 24.8 g per 100 patient days in
1992 to 18.5 g per 100 patient days in 1995. The number of cours-
es, a parameter that takes the prophylactic use into account,
decreased by 62% from 2.3 per 100 patient days in 1992 to 0.9 per
100 patient days in 1995. The percentage of sensitive strains
increased from 54.9% (n=512) in 1992 and 54.0% (n=506) in 1993 to
72.1% (n=546) in 1994 and 83.1% (n=668) in 1995. No major changes
were detected for other antimicrobials, such as cotrimoxazole,
tetracycline, or cefuroxime, used in this 4-year period.
CONCLUSIONS: A decrease in the use of amoxicillin-
clavulanate was followed by an increase in susceptibility of E coli
to it. It was not possible to prove a causative relationship. Only a
temporal association was discovered. The reduction of the use of
amoxicillin-clavulanate was achieved through the implementation
of treatment guidelines, facilitated through a close collaboration
among the clinical pharmacists, the infection control practitioner,
the microbiology laboratory, and the physicians in charge of the
respective departments (Infect Control Hosp Epidemiol
1998;19:653-656).
Several articles have been published that show a
connection between the use of antimicrobials and the
development of resistance. In 1979, Buckwold and Ronald1
discussed this issue and proposed improved medical edu-
cation, the adaptation of a policy restricting the use of spe-
cific antimicrobial agents, the introduction of guidelines,
and a close collaboration among hospital infection and
pharmacy committees and the clinical microbiology labo-
ratories. Hollmann2 analyzed data on antimicrobial con-
sumption and resistance patterns in 1980 and discovered a
correlation. In 1983, Daschner et al3 stated that the restric-
tion of the use of antimicrobials often leads to a decrease
in resistance rates. In 1983, McGowan4 compiled a review
of studies performed from 1950 to 1980, which showed a
relation between antibiotic use and resistance. In 1987, he
assumed that epidemiological criteria for a causal relation-
ship between antibiotic use and resistance of hospital
organisms was supported by new data despite confound-
ing variables inherent in the studies.5 In 1994, McGowan
stated that the temporal association between resistance
and use already asked for the development of appropriate
measures such as education of prescribers, the implemen-
tation of restrictions, and intensive control programs.6
Several authors published data that compared specific
antimicrobials with specific species of bacteria. Ma et al
reported a substantial decrease in cephalosporin resis-
tance in gram-negative bacilli after a marked decrease in
prescribing of these drugs.7 Data on antibiotic purchases
and bacterial susceptibilities in 18 hospitals in the United
States revealed a statistically significant correlation
between increasing ceftazidime use and increasing Enter-
obacter cloacae resistance.8 Richard et al reported the
results of a case-control study and found that treatment
with fluoroquinolones was an independent risk factor for
nosocomial infections caused by fluoroquinolone-resistant
gram-negative bacilli.9
Sanders and Sanders10 published a review of resis-
tance to b-lactam antibiotics in gram-negative rods. There
are several possible factors determining resistance to amox-
icillin-clavulanate in Escherichia coli. One is TEM-1 b-lacta-
mase hyperproduction.11-13 Another mechanism of resis-
tance may be an altered permeability of the outer cell mem-
brane.14 Others described mutations in the genes encoding
for TEM-1 b-lactamases.15-17 Published data on the rate of
resistance to amoxicillin-clavulanate in E coli vary consider-
ably. In France, isolates from urine in 1993 showed 25% of
strains were resistant, and 15% were intermediate.11 On
the other hand, a survey of isolates from six intensive-care
units in Switzerland in 1994 showed 93% of strains were
sensitive.18 Kastanakis et al from Crete reported that 18%
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of strains in urine and 30% of strains from other sources
were resistant,19 whereas Kouppari et al20 reported less
than 2% of strains isolated from neonates in the Children’s
Hospital in Athens were resistant.
METHODS
Setting
The present study was conducted at a 260-bed acute-
care hospital in Schaffhausen, Switzerland. The data from
the four major departments (surgery, internal medicine,
obstetrics-gynecology, and the interdisciplinary intensive-
care unit) have been analyzed, amounting to approximate-
ly 65,000 to 70,000 patient days per year.
Antibiotic Consumption
The hospital pharmacy’s annual analysis of the
amount of antimicrobials delivered to all of the departments
in the hospital has been calculated in two different ways:
1. In gram of substance; this parameter showed the
total amount of the drugs used in the hospital.
2. In number of courses; this parameter indicated how
many times the decision to use amoxicillin-clavulanate was
made. This was of particular interest because the interven-
tions taken concerned the prophylactic use of the drug, as
well as the dosages. The following assumptions have been
made: (1) the quantities of prophylactic courses were known
from a survey of all surgical patients in 1993 and from the
number of hysterectomies and cesarean sections performed
in the hospital; (2) for therapeutic use, an average duration
of treatment of 7 days has been assumed for the ward and 3
days for the intensive-care unit (according to the average
length of stay in that unit).
Surveillance of Resistance
Data from routine resistance testing in the microbi-
ology laboratory were analyzed using a computer program
(ResiMed, written by M. L. Mueller and C. Conrad21). The
system eliminated duplicate specimens if the isolates came
from the same patient in the same material and with the
same resistance pattern. The fact that isolates from multi-
ple sites from the same patient are included in the analysis
did not have any influence on the results.
Routine resistance testing was performed by the disc
diffusion method22 using culture media from Bio-Life
(Milan, Italy) and antibiotic discs from Becton-Dickin-
son–Europe (Meylan, France).
Control of the Resistance Testing
Between November 1994 and February 1995, 30 con-
secutive isolates determined by routine testing to be inter-
mediately sensitive to amoxicillin-clavulanate were collected.
Their susceptibility was tested again using materials from
different manufacturers. For the disc diffusion method,22
antibiotic discs from Becton-Dickinson, as well as from
Sanofi (Sanofi Diagnostics Pasteur, Marnes La Coquette,
France) were used. To determine the minimum inhibitory
concentrations, E-Test-strips (AB Biodisk, Solna, Sweden)
were used. Both methods were performed on culture media
from Bio-Life, as well as from Sanofi. The interpretation of
the results was made according to the guidelines of the
National Committee for Clinical Laboratory Standards.22
Interventions
To influence the use of amoxicillin-clavulanate, the
following interventions were undertaken:
● In the guidelines for the prophylactic and thera-
peutic use of antimicrobials in the department of gynecolo-
gy and obstetrics, implemented at the beginning of 1993,
the use of amoxicillin-clavulanate was abandoned com-
pletely. For prophylaxis, amoxicillin was substituted alone,
because these patients usually come directly from home
and are not expected to carry nosocomial pathogens. For
treatment, cefuroxime was introduced instead.
● In the guidelines for treatment of urinary tract
infections, introduced in all departments in October 1994,
cefuroxime replaced amoxicillin-clavulanate for the indica-
tions “pyelonephritis” and “urosepsis.”
● In the guidelines for perioperative antimicrobial
prophylaxis in the department of surgery, introduced at the
beginning of 1995, amoxicillin-clavulanate was replaced by
cefoxitin.
● For the treatment of infections caused by Staphylo-
coccus aureus and for soft-tissue infections, it was proposed
that flucloxacillin be used whenever possible.
● Furthermore, it was advised that amoxicillin-clavu-
lanate be used in a very restricted manner in the intensive-
care unit.
All of these changes were made in close interdisci-
plinary collaboration among the physicians, the clinical
pharmacist, and the infection control practitioner and on
the basis of comprehensive surveillance data. The imple-
mentations consisted of oral presentations of the new
guidelines, information for all prescribing physicians, and
the introduction of the guidelines in the handbooks of the
departments. Beginning in 1993, all physicians new at the
hospital were trained by the infection control practitioner
and the clinical pharmacist about the local situation con-
cerning resistance problems and guidelines for use. Addi-
tionally, a consultation service running during working
hours and daily ward rounds of the infection control practi-
tioner and the clinical pharmacist were implemented.
RESULTS
Use of Amoxicillin-Clavulanate
The total amount of amoxicillin-clavulanate used
decreased over the period of 4 years by 23%, from 24.8 g per
100 patient days in 1992 to 18.5 g per 100 patient days in 1995.
The number of courses over the same period dropped by
almost 62%, from 2.3 per 100 patient days in 1992 to 0.9 per
100 patient days in 1995. Detailed data are shown in Table 1.
Development of Resistance
There was a continuous increase in the susceptibility
of E coli to amoxicillin-clavulanate since 1994. In 1992,
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54.9% of the 512 strains isolated were sensitive, and in 1993,
54% of 506 strains were sensitive. But this percentage
increased in 1994 to 72.1% (n=546), and in 1995 to 83.1%
(n=668). Surprisingly, in 1992 a high percentage of inter-
mediate strains were isolated, 27.9%, which decreased to
11.2% in 1995. In 1992, 17.2% of strains were resistant, and
this figure decreased to 5.7% in 1995. The detailed data are
summarized in Table 2.
Use and Resistance of Other Antimicrobials
Three other antimicrobials used over the 4-year peri-
od from 1992 to 1995 were evaluated: cotrimoxazole, tetra-
cycline, and cefuroxime. No major changes in susceptibili-
ty could be detected. The susceptibility of E coli remained
stable to cotrimoxazole and tetracycline with 80.7% to 87.6%
and 68.3% to 75.7%, respectively, and even increased to
cefuroxime from 87.4% to 96.8%. The amount of the drug
used varied for cotrimoxazole, doubled for tetracycline, and
increased 10-fold for cefuroxime (Table 3).
The use of broad-spectrum antimicrobials increased
from 1992 to 1995, but no changes were detected in the
resistance pattern of E coli. Because these substances were
not in use during the entire 4-year period, the data are not
shown in detail.
Validation of the Routine Resistance Testing
Control assays of intermediate strains from the rout-
ing testing yielded homogeneous results. For the agar disc
diffusion tests, the diameters measured lay between 11 and
21 mm and their averages between 14.5 and 16.6 mm,
depending on the materials used. Determination of the min-
imum inhibitory concentration by E-test resulted in values
from 4 to 16 µg/mL, with averages between 10.3 and 11.8
µg/mL. The different test media yielded the same results.
Cross-Resistance
E coli strains with decreased susceptibility to amoxi-
cillin-clavulanate also had decreased susceptibility to first-
generation cephalosporins, cotrimoxazole, and tetracy-
cline, and, to a lesser extent, to second- and third-genera-
tion cephalosporins (Table 4). There were only a few
strains intermediately sensitive or resistant to tobramycin,
imipenem, or piperacillin-tazobactam.
DISCUSSION
In the present study, a decrease in the use of amoxi-
cillin-clavulanate was followed by an increase in suscepti-
TABLE 1
CONSUMPTION OF AMOXICILLIN-CLAVULANATE BY SERVICE AND YEAR
Use per 100 Patient Days
Internal Obstetrics- Intensive-
Surgery Medicine Gynecology Care Unit Total
Year Grams  Courses Grams   Courses Grams   Courses Grams   Courses Grams   Courses
1992 22.0 2.4 23.3 1.4 23.7 3.6 98.8 6.8 24.8 2.3
1993 22.5 2.2 27.9 1.3 2.3 0.2 70.1 4.0 22.5 1.5
1994 19.9 2.0 21.5 1.0 1.1 0.1 53.3 3.0 18.2 1.3
1995 17.3 0.8 24.2 1.1 2.7 0.2 52.7 3.3 18.5 0.9
1995 vs 1992 221.4% 265.5% +3.8% 224.3% 288.6% 295.2% 246.6% 251.3% 223.0% 261.8%
TABLE 2
RESISTANCE IN ESCHERICHIA COLI TO AMOXICILLIN-CLAVULANATE BY SERVICE AND YEAR
Percentage of Strains Categorized as (R)esistant, (I)ntermediate, and (S)ensitive
Internal Obstetrics- Intensive-
Surgery Medicine Gynecology Care Unit Total
Year R        I        S R       I      S R      I       S R       I       S R       I       S
1992 32.4 23.4 44.2 14.7 30.7 54.6 6.8 39.0 54.2 34.9 30.2 34.9 17.2 27.9 54.9
1993 23.0 21.2 55.8 16.7 31.0 52.3 14.5 36.1 49.4 29.3 27.6 43.1 16.8 29.2 54.0
1994 24.7 25.3 50.0 2.9 21.4 75.7 0 17.0 83.0 36.2 24.6 39.1 9.2 18.7 72.1
1995 5.1 11.3 83.6 7.9 13.0 79.1 7.7 13.9 78.4 6.3 12.5 81.3 5.7 11.2 83.1
TABLE 3
CONSUMPTION AND RESISTANCE PATTERNS OF OTHER
ANTIMICROBIALS FROM 1992 TO 1995 (ALL DEPARTMENTS)
Use in Grams per 100 Patient Days 
(% Sensitive)
Antibiotic 1992 1993 1994 1995
Cotrimoxazole 4.8  (86.1) 10.5  (87.6) 5.4  (80.7) 3.3  (84.1)
Tetracycline 0.0  (71.4) 0.1  (68.3) 0.1  (69.5) 0.1  (75.7)
Cefuroxime 0.4  (87.4) 0.8  (94.6) 0.9  (95.4) 3.7  (96.8)
https://doi.org/10.2307/30141529
Downloaded from https:/www.cambridge.org/core. University of Basel Library, on 11 Jul 2017 at 11:08:21, subject to the Cambridge Core terms of use, available at https:/www.cambridge.org/core/terms.
656 INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY September 1998
bility of E coli to it. The reduction in amoxicillin-clavulanate
use was achieved mainly through the introduction of treat-
ment guidelines into daily clinical practice, in which alter-
native antibiotics were suggested whenever possible.
It is not possible to show a causative relationship
between these two parameters, but there was a clear tem-
poral association between antibiotic-use restriction and
resistance patterns.
During the study period, a dramatic increase in the
use of cefuroxime occurred. Thus far, this has not had any
adverse effect on resistance rates. However, use and sus-
ceptibility must be monitored closely in the future, because
follow-up monitoring of the present study was short, with
only 4 years’ worth of data.
The high percentage of intermediate strains in E coli
raised doubts as to the appropriateness of the routine test-
ing. However, control tests performed with materials from
different manufacturers yielded the same results and thus
confirmed the data.
The mechanism of resistance was not proven, but
analysis of the pattern of cross-resistance could imply that
the cause of resistance may be overproduction of TEM-1 b-
lactamases, as described in the introduction.
An important aspect of the present study was that all
actions were taken in close collaboration with the clinical
pharmacists, the infection control practitioner, the microbi-
ology laboratory, and the physicians in charge of the respec-
tive departments. This interdisciplinary approach facilitated
the implementation of the necessary measures. Ongoing
surveillance of the development of resistance, as well as the
use of antibiotics in a specific setting, are an important pro-
cedural basis from which to detect any adverse events as
soon as possible and to take appropriate measures. This
procedure will allow control over, and will restrict the use of,
antibiotics, as well as the development of resistance.
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